462 related articles for article (PubMed ID: 28943450)
1. Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis.
Rupp C; Bode KA; Leopold Y; Sauer P; Gotthardt DN
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1380-1389. PubMed ID: 28943450
[TBL] [Abstract][Full Text] [Related]
2. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma.
Chung BK; Karlsen TH; Folseraas T
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1390-1400. PubMed ID: 28844951
[TBL] [Abstract][Full Text] [Related]
3. S100A9 is a biliary protein marker of disease activity in primary sclerosing cholangitis.
Reinhard L; Rupp C; Riedel HD; Ruppert T; Giese T; Flechtenmacher C; Weiss KH; Kloeters-Plachky P; Stremmel W; Schirmacher P; Sauer P; Gotthardt DN
PLoS One; 2012; 7(1):e29821. PubMed ID: 22253789
[TBL] [Abstract][Full Text] [Related]
4. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis.
Lankisch TO; Metzger J; Negm AA; Vosskuhl K; Schiffer E; Siwy J; Weismüller TJ; Schneider AS; Thedieck K; Baumeister R; Zürbig P; Weissinger EM; Manns MP; Mischak H; Wedemeyer J
Hepatology; 2011 Mar; 53(3):875-84. PubMed ID: 21374660
[TBL] [Abstract][Full Text] [Related]
5. Calprotectin in bile: a disease severity marker in patients with primary sclerosing cholangitis.
Voigtländer T; Wlecke J; Negm AA; Lenzen H; Manns MP; Lankisch TO
J Clin Gastroenterol; 2014; 48(10):866-9. PubMed ID: 24440929
[TBL] [Abstract][Full Text] [Related]
6. Bile duct expression of pancreatic and duodenal homeobox 1 in perihilar cholangiocarcinogenesis.
Igarashi S; Matsubara T; Harada K; Ikeda H; Sato Y; Sasaki M; Matsui O; Nakanuma Y
Histopathology; 2012 Aug; 61(2):266-76. PubMed ID: 22594685
[TBL] [Abstract][Full Text] [Related]
7. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma.
Bergquist A; Glaumann H; Stål P; Wang GS; Broomé U
J Intern Med; 2001 Jan; 249(1):69-75. PubMed ID: 11168786
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma.
Voigtländer T; Gupta SK; Thum S; Fendrich J; Manns MP; Lankisch TO; Thum T
PLoS One; 2015; 10(10):e0139305. PubMed ID: 26431155
[TBL] [Abstract][Full Text] [Related]
9. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.
Metzger J; Negm AA; Plentz RR; Weismüller TJ; Wedemeyer J; Karlsen TH; Dakna M; Mullen W; Mischak H; Manns MP; Lankisch TO
Gut; 2013 Jan; 62(1):122-30. PubMed ID: 22580416
[TBL] [Abstract][Full Text] [Related]
10. TLR4, TLR9, and NLRP3 in biliary epithelial cells of primary sclerosing cholangitis: relationship with clinical characteristics.
Matsushita H; Miyake Y; Takaki A; Yasunaka T; Koike K; Ikeda F; Shiraha H; Nouso K; Yamamoto K
J Gastroenterol Hepatol; 2015 Mar; 30(3):600-8. PubMed ID: 25160604
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study.
Bergquist A; Glaumann H; Persson B; Broomé U
Hepatology; 1998 Feb; 27(2):311-6. PubMed ID: 9462625
[TBL] [Abstract][Full Text] [Related]
12. Neoplastic Transformation of the Peribiliary Stem Cell Niche in Cholangiocarcinoma Arisen in Primary Sclerosing Cholangitis.
Carpino G; Cardinale V; Folseraas T; Overi D; Grzyb K; Costantini D; Berloco PB; Di Matteo S; Karlsen TH; Alvaro D; Gaudio E
Hepatology; 2019 Feb; 69(2):622-638. PubMed ID: 30102768
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence.
Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
Am J Surg Pathol; 2007 Jun; 31(6):907-13. PubMed ID: 17527079
[TBL] [Abstract][Full Text] [Related]
14. Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology.
Pinto C; Giordano DM; Maroni L; Marzioni M
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1270-1278. PubMed ID: 28754451
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium.
Strazzabosco M; Fiorotto R; Cadamuro M; Spirli C; Mariotti V; Kaffe E; Scirpo R; Fabris L
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1374-1379. PubMed ID: 28754453
[TBL] [Abstract][Full Text] [Related]
16. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228
[TBL] [Abstract][Full Text] [Related]
17. Clinical clues to suspicion of IgG4-associated sclerosing cholangitis disguised as primary sclerosing cholangitis or hilar cholangiocarcinoma.
Oh HC; Kim MH; Lee KT; Lee JK; Moon SH; Song TJ; Eum J; Park DH; Lee SS; Seo DW; Lee SK
J Gastroenterol Hepatol; 2010 Dec; 25(12):1831-7. PubMed ID: 21091993
[TBL] [Abstract][Full Text] [Related]
18. On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease.
Trampert DC; Hubers LM; van de Graaf SFJ; Beuers U
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1401-1409. PubMed ID: 28782655
[TBL] [Abstract][Full Text] [Related]
19. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
20. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis.
Björnsson E; Boberg KM; Cullen S; Fleming K; Clausen OP; Fausa O; Schrumpf E; Chapman RW
Gut; 2002 Nov; 51(5):731-5. PubMed ID: 12377815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
